Vasculitis & polymyalgia rheumatica
Comparative Real‐World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet Disease
Authors' conclusion
In Behçet disease, interferon alfa-2a was associated with a reduction in uveitis relapse compared with cyclosporine, whereas adalimumab demonstrated a stronger association with reduced relapse than interferon alfa-2a.
Study context
- Population
- Adults with BD uveitis initiating cyclosporine, interferon alfa-2a or adalimumab, April 10, 2008–August 1, 2024
- Participants
- 716 / 193 / 103
- Exposure
- Cyclosporine vs interferon alfa-2a vs adalimumab
- Cyclosporinen = 716
- Interferon alfa-2an = 193
- Adalimumabn = 103
- Outcome
- Annualized relapse rate of uveitis during treatment with study therapy
Methodological detailsobservational cohort study, overlap weighting, real-world, Patients observed up until September 10, 2024
- Observational cohort study
- Overlap weighting
- Real-world
- Patients observed up until September 10, 2024
Main finding
As reported in the abstract
Annualized uveitis relapse rate (estimated mean)
Cyclosporine
0.95
mean · 95% CI 0.82–1.10
Interferon alfa-2a
0.52
mean · 95% CI 0.40–0.69
Adalimumab
0.28
mean · 95% CI 0.19–0.43
Incidence rate ratio (95% CI)P value
Cyclosporinevs Adalimumab
3.36(2.23–5.05)
P < 0.001Cyclosporinevs Interferon alfa-2a
1.81(1.37–2.4)
P < 0.001Interferon alfa-2avs Adalimumab
1.86(1.16–2.97)
P = 0.011Mean difference (95% CI)P value
Cyclosporinevs Adalimumab
0.66(0.48–0.85)
P < 0.001Cyclosporinevs Interferon alfa-2a
0.42(0.22–0.62)
P < 0.001Interferon alfa-2avs Adalimumab
0.24(0.05–0.43)
P = 0.011Observational data: associations, not effects.
Original publication
Comparative Real‐World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet Disease. Arthritis Rheumatol. Published 9 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →